News About: Pharm. Industry
Handok, Lilly Korea to join forces in Cymbalta
Lilly Korea and Handok Pharm said on June 22 that they have agreed to join hands to market Cymbalta (duloxetine HCl) in Korea.
To this end, the two companies exchanged a letter of intent to make Cymbalta more compe...
Merck launches Collaborative Cancer Trials Network
Merck & Co said it has launched the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatmen...
Dual-purpose drugs perk up sales
Various combination therapies made up 13.6 percent of the domestic drug market in 2009, representing the fastest-growing segment of that market, according to Ubist data.
Daewoong’s Olmetec Plus tablets topped 46.7 ...
FTC to look into drugmakers
Korea’s antitrust regulator has embarked on looking into the intellectual property rights of the pharmaceutical industry following its longstanding investigation into the drug makers’ undue business practices such as ...
Dumping war looming in pharmaceutical and wholesaling industries
Recent unfair biddings in hospitals has produced negative side effects that require the attention of drugmakers and wholesalers, including the possibility of predatory pricing, commonly referred to as “dumping.”
Ma...
OTC drugmakers eye price hike
Some pharmaceutical firms are soon considering a price hike of their products in order to make up for their margins lost by sluggish sales, industry sources said.
Handok Pharm said it plans to hike the price of Fe...
Product patent potential tool in Japanese drug market
Korean drugmakers need to develop a variety of product patents to successfully penetrate into the Japanese pharmaceutical market, said a local examiner at the Korea Intellectual Property Office.
KIPO is one of the ...
Chinese, Indian Pharmaceutical markets have been growing
The pharmaceutical industries in China and India are expected to achieve a double digit growth of 14-17 percent by 2014, according to the Korea Pharmaceutical Traders Association.
In a local workshop, a KPTA offici...
Xolair improves patients' asthma-related quality of life
Results of a clinical study presented at a local congress of the Korean Academy of Asthma, Allergy and Clinical Immunology show that Xolair (omalizumab) reduced the rate of severe asthma exacerbations in patients with...
Drugmakers likely to be hit by new drug-pricing reform
The government’s plan to gradually lower drug prices, which is to be implemented in October, has stirred up concerns among drug companies.
They fear that the new initiative could not only slash their profits but p...
